Characteristics of the CALRMUT patients studied compared with JAK2V617F and triple-negative patients
| Parameter . | Total . | JAK2V617F . | CALRMUT . | Triple negative . | P value for CALRMUT vs JAK2V617F . | P value for CALRMUT vs triple negative . |
|---|---|---|---|---|---|---|
| No. (% of cohort) | 105* | 43 (41%) | 26 (25%) | 34 (33%) | ||
| Age at diagnosis, years, median (range)† | 47 (10-84) | 54 (25-84) | 31 (10-71) | 40 (14-77) | .0002 | .2 |
| Platelet count at diagnosis, ×109/L, median (range)‡ | 807 (456-4875) | 800 (523-1140) | 1169 (500-4875) | 721 (456-2800) | .001 | .1 |
| Age at first test, years, median (range) | 50 (10-92) | 61 (25-92) | 37 (10-89) | 49 (16-89) | .003 | .8 |
| Months from diagnosis at first test, median (range)† | 18 (0-297) | 20 (0-217) | 40 (0-175) | 12 (0-297) | .5 | .3 |
| % Mutant, median (range) | 18% (5-100%)§ | 50% (22-56%) | <.0001 | |||
| % Mutant at or within 3 mo of diagnosis, median (range) | 17% (10-42%) | 46% (27-56%) | .0001 | |||
| XCIP status, clonal:polyclonal (%) | 22:39 (36%:64%) | 6:17 (26%:74%) | 14:2 (88%:12%) | 2:20 (9%:91%) | .0002¶ | <.0001¶ |
| Parameter . | Total . | JAK2V617F . | CALRMUT . | Triple negative . | P value for CALRMUT vs JAK2V617F . | P value for CALRMUT vs triple negative . |
|---|---|---|---|---|---|---|
| No. (% of cohort) | 105* | 43 (41%) | 26 (25%) | 34 (33%) | ||
| Age at diagnosis, years, median (range)† | 47 (10-84) | 54 (25-84) | 31 (10-71) | 40 (14-77) | .0002 | .2 |
| Platelet count at diagnosis, ×109/L, median (range)‡ | 807 (456-4875) | 800 (523-1140) | 1169 (500-4875) | 721 (456-2800) | .001 | .1 |
| Age at first test, years, median (range) | 50 (10-92) | 61 (25-92) | 37 (10-89) | 49 (16-89) | .003 | .8 |
| Months from diagnosis at first test, median (range)† | 18 (0-297) | 20 (0-217) | 40 (0-175) | 12 (0-297) | .5 | .3 |
| % Mutant, median (range) | 18% (5-100%)§ | 50% (22-56%) | <.0001 | |||
| % Mutant at or within 3 mo of diagnosis, median (range) | 17% (10-42%) | 46% (27-56%) | .0001 | |||
| XCIP status, clonal:polyclonal (%) | 22:39 (36%:64%) | 6:17 (26%:74%) | 14:2 (88%:12%) | 2:20 (9%:91%) | .0002¶ | <.0001¶ |
P values are the Student unpaired t test unless otherwise stated.
Two patients were MPLMUT.
Date of diagnosis was unknown in 10 patients: 2 JAK2V617F, 3 CALRMUT, and 5 triple negative.
Platelet count at diagnosis was unknown in 13 patients: 4 JAK2V617F, 3 CALRMUT, and 6 triple negative.
The 1 patient with a mutant level >50% had post-ET myelofibrosis at the time of analysis.
Two-sided Fisher's exact test.